Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-053703
Filing Date
2025-04-14
Accepted
2025-04-14 16:05:05
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A kytx_-_defa14a_proxy_not.htm DEFA14A 16867
2 GRAPHIC img10335942_0.jpg GRAPHIC 1132488
3 GRAPHIC img10335942_1.jpg GRAPHIC 715138
  Complete submission text file 0000950170-25-053703.txt   2562466
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41947 | Film No.: 25836040
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)